MX2022011748A - Composiciones orales de inhibidor de ruta de mk2 para el tratamiento de condiciones inmunitarias. - Google Patents
Composiciones orales de inhibidor de ruta de mk2 para el tratamiento de condiciones inmunitarias.Info
- Publication number
- MX2022011748A MX2022011748A MX2022011748A MX2022011748A MX2022011748A MX 2022011748 A MX2022011748 A MX 2022011748A MX 2022011748 A MX2022011748 A MX 2022011748A MX 2022011748 A MX2022011748 A MX 2022011748A MX 2022011748 A MX2022011748 A MX 2022011748A
- Authority
- MX
- Mexico
- Prior art keywords
- oral
- treatment
- inhibitor compositions
- immune conditions
- compound
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000004968 inflammatory condition Effects 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (16)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063000746P | 2020-03-27 | 2020-03-27 | |
| US202063015241P | 2020-04-24 | 2020-04-24 | |
| US202063018954P | 2020-05-01 | 2020-05-01 | |
| US202063022301P | 2020-05-08 | 2020-05-08 | |
| US202063022298P | 2020-05-08 | 2020-05-08 | |
| US202063024160P | 2020-05-13 | 2020-05-13 | |
| US202063053903P | 2020-07-20 | 2020-07-20 | |
| US202063076689P | 2020-09-10 | 2020-09-10 | |
| US202063126173P | 2020-12-16 | 2020-12-16 | |
| US202063128523P | 2020-12-21 | 2020-12-21 | |
| US202163136080P | 2021-01-11 | 2021-01-11 | |
| US202163136967P | 2021-01-13 | 2021-01-13 | |
| US202163138672P | 2021-01-18 | 2021-01-18 | |
| US202163140116P | 2021-01-21 | 2021-01-21 | |
| US202163149230P | 2021-02-13 | 2021-02-13 | |
| PCT/US2021/024482 WO2021195562A1 (en) | 2020-03-27 | 2021-03-26 | Oral compositions of mk2 pathway inhibitor for treatment of immune conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011748A true MX2022011748A (es) | 2022-12-02 |
Family
ID=77890611
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011748A MX2022011748A (es) | 2020-03-27 | 2021-03-26 | Composiciones orales de inhibidor de ruta de mk2 para el tratamiento de condiciones inmunitarias. |
| MX2022011755A MX2022011755A (es) | 2020-03-27 | 2021-03-26 | Proceso, composiciones y formas cristalinas de compuestos de piridinona-piridinilo sustituidos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011755A MX2022011755A (es) | 2020-03-27 | 2021-03-26 | Proceso, composiciones y formas cristalinas de compuestos de piridinona-piridinilo sustituidos. |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20230149400A1 (https=) |
| EP (2) | EP4132524A4 (https=) |
| JP (2) | JP2023519890A (https=) |
| KR (2) | KR20220161396A (https=) |
| CN (4) | CN119235863A (https=) |
| AU (2) | AU2021244255A1 (https=) |
| BR (1) | BR112022019349A2 (https=) |
| CA (2) | CA3172088A1 (https=) |
| IL (1) | IL296054A (https=) |
| MX (2) | MX2022011748A (https=) |
| PH (2) | PH12022552321A1 (https=) |
| WO (3) | WO2021195507A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220161396A (ko) | 2020-03-27 | 2022-12-06 | 어클라리스 쎄라퓨틱스, 인코포레이티드 | 치환된 피리디논-피리디닐 화합물의 제조, 조성물, 및 결정형 |
| KR20230044446A (ko) * | 2020-07-24 | 2023-04-04 | 브리스톨-마이어스 스큅 컴퍼니 | 급성 호흡기 장애의 치료 방법 |
| EP4247380A4 (en) * | 2020-11-23 | 2025-03-05 | Aclaris Therapeutics, Inc. | PROCESSES FOR THE SYNTHESIS OF SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS |
| BR112023019861A2 (pt) | 2021-03-31 | 2023-11-07 | Xinthera Inc | Inibidores de mk2 e usos dos mesmos |
| EP4367099A4 (en) | 2021-07-09 | 2025-06-04 | Xinthera, Inc. | Pyridinone mk2 inhibitors and uses thereof |
| WO2023125708A1 (zh) * | 2021-12-29 | 2023-07-06 | 上海美悦生物科技发展有限公司 | 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途 |
| CN116396274B (zh) * | 2022-01-06 | 2025-11-11 | 深圳信立泰药业股份有限公司 | 一种取代的联吡啶酮类化合物及其制备方法与应用 |
| CN116444493A (zh) * | 2022-01-14 | 2023-07-18 | 上海翰森生物医药科技有限公司 | 含双并环类衍生物、其制备方法和应用 |
| WO2023150709A2 (en) * | 2022-02-04 | 2023-08-10 | Aclaris Therapeutics, Inc. | Methods of synthesizing deuterated substituted pyridinone-pyridinyl compounds |
| EP4593823A1 (en) * | 2022-09-30 | 2025-08-06 | Abbvie Inc. | Methods of treating hidradenitis suppurativa |
| TW202428271A (zh) * | 2022-11-16 | 2024-07-16 | 大陸商上海美悦生物科技發展有限公司 | 吡啶氮氧化物類衍生物及其藥物組合物、製備方法和用途 |
| KR20240078816A (ko) | 2022-11-28 | 2024-06-04 | 주식회사 엘지에너지솔루션 | 에이징 시스템 |
| EP4650347A1 (en) | 2023-01-13 | 2025-11-19 | Shanghai Meiyue Biotech Development Co., Ltd. | Phenyl-substituted heteroaryl compound and pharmaceutical composition comprising same, preparation method therefor and use thereof |
| JP2026504073A (ja) * | 2023-01-13 | 2026-02-03 | プールベグ ファーマ（ユーケー） リミテッド | がん免疫療法関連サイトカイン放出症候群の軽減のための医薬品および方法 |
| WO2025093869A1 (en) * | 2023-11-01 | 2025-05-08 | Poolbeg Pharma (UK) Limited | P38 map kinase inhibitor for use in the treatment of inflammation |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| JP2002526482A (ja) | 1998-09-18 | 2002-08-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | ｐ３８のインヒビター |
| JP2003500403A (ja) | 1999-05-21 | 2003-01-07 | サイオス，インコーポレーテッド | ｐ３８キナーゼのインヒビターとしてのインドール型誘導体 |
| EP1248869A2 (en) * | 2000-01-07 | 2002-10-16 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
| EP1341782A2 (en) | 2000-11-20 | 2003-09-10 | Scios Inc. | Inhibitors of p38 kinase |
| US7314752B2 (en) | 2001-07-19 | 2008-01-01 | Common Sense, Ltd. | Secretion-monitoring article |
| ATE448784T1 (de) | 2002-02-14 | 2009-12-15 | Pharmacia Corp | Substituierte pyridinone als modulatoren für p38 map kinase |
| US7304061B2 (en) | 2002-04-26 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of ERK2 and uses thereof |
| GB0218630D0 (en) | 2002-08-10 | 2002-09-18 | Tanabe Seiyaku Co | Novel compounds |
| CA2498111A1 (en) | 2002-09-11 | 2004-03-25 | Merck & Co., Inc. | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors |
| US7183287B2 (en) | 2003-04-03 | 2007-02-27 | Pharmacia Corporation | Substituted pyrimidinones |
| US20070167621A1 (en) | 2003-04-03 | 2007-07-19 | Pharmacia Corporation | Substituted pyrimidinones |
| CL2004002050A1 (es) | 2003-08-13 | 2005-06-03 | Pharmacia Corp Sa Organizada B | Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros. |
| US20060014741A1 (en) * | 2003-12-12 | 2006-01-19 | Dimarco John D | Synthetic process, and crystalline forms of a pyrrolotriazine compound |
| GB0402653D0 (en) * | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
| JP2005255675A (ja) | 2004-02-09 | 2005-09-22 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| CN1976915A (zh) | 2004-02-11 | 2007-06-06 | 史密丝克莱恩比彻姆公司 | Hiv整合酶抑制剂 |
| US7936407B2 (en) | 2005-02-24 | 2011-05-03 | Samsung Electronics Co., Ltd. | Array substrate, method of manufacturing the same, display panel having the same, and liquid crystal display apparatus having the same |
| BRPI0607913A2 (pt) | 2005-04-08 | 2010-03-23 | Eisai R&D Man Co Ltd | agente terapÊutico para discinesia |
| TW200740755A (en) | 2005-07-13 | 2007-11-01 | Bayer Cropscience Sa | Dihalogenation of N,O-disubstituted hydroxypyridones and their uses |
| WO2007081901A2 (en) | 2006-01-05 | 2007-07-19 | The Scripps Research Institute | Pyrimidinone derivatives as protein kinase inhibitors |
| UY30378A1 (es) | 2006-06-02 | 2008-01-02 | Janssen Pharmaceutica Nv | Nuevos derivados de piridinona n-aril y n-heteroaril sustituidos para usar en enfermedades mediadas por mch-1 |
| ES2426780T3 (es) | 2006-07-14 | 2013-10-25 | Amgen Inc. | Compuestos de piridona sustituidos con alquino y métodos de uso |
| KR20090085117A (ko) | 2006-11-24 | 2009-08-06 | 다케다 야쿠힌 고교 가부시키가이샤 | 헤테로모노시클릭 화합물 및 이의 용도 |
| BRPI0720049A2 (pt) | 2006-12-07 | 2014-01-07 | Novartis Ag | Derivados de piridina utilizados como inibidores de xiap |
| US20110130403A1 (en) * | 2007-03-14 | 2011-06-02 | Ranbaxy Laboratories Limited | Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors |
| WO2008153942A1 (en) | 2007-06-06 | 2008-12-18 | Xcovery, Inc. | Kinase inhibitor compounds |
| EA016595B1 (ru) | 2007-07-17 | 2012-06-29 | Бристол-Маерс Сквибб Компани | Способ модулирования рецептора gpr119, сопряженного с g-белком, и используемые при этом соединения |
| US9187426B2 (en) | 2008-06-27 | 2015-11-17 | Novartis Ag | Organic compounds |
| EP2334673A1 (en) * | 2008-08-29 | 2011-06-22 | Amgen Inc. | PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF |
| JP5466759B2 (ja) | 2009-05-28 | 2014-04-09 | ノバルティス アーゲー | ネプリライシン阻害剤としての置換アミノ酪酸誘導体 |
| US8618299B2 (en) | 2009-07-01 | 2013-12-31 | Albany Molecular Research, Inc. | Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof |
| US9073925B2 (en) | 2009-07-01 | 2015-07-07 | Albany Molecular Research, Inc. | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
| WO2011003007A1 (en) | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof |
| AU2010302420B2 (en) * | 2009-10-02 | 2013-07-04 | Astrazeneca Ab | 2-pyridone compounds used as inhibitors of neutrophil elastase |
| SI2648516T1 (sl) | 2010-12-06 | 2019-01-31 | Aclaris Therapeutics, Inc. | Substituirane spojine piridinon-piridinila |
| US9056110B2 (en) | 2011-12-06 | 2015-06-16 | Confluence Life Sciences, Inc. | Substituted pyrimidinone-phenyl-pyrimidinyl compounds |
| HUE054178T2 (hu) * | 2013-06-07 | 2021-08-30 | Aclaris Therapeutics Inc | Metil/fluor-piridinil-metoxi-szubsztituált piridinon-piridinil-vegyületek és fluor-pirimidinil-metoxi-szubsztituált piridinon-piridinil-vegyületek |
| WO2015161908A1 (en) * | 2014-03-11 | 2015-10-29 | Ludwig-Maximilians-Universität München | Non-immunosuppressive cyclophilin inhibitors for the treatment of coronavirus infections |
| WO2017048702A1 (en) * | 2015-09-14 | 2017-03-23 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| EP3720436A4 (en) | 2017-12-06 | 2021-06-02 | Lin Bioscience, Pty Ltd. | TUBULIN INHIBITORS |
| JP2022542434A (ja) | 2019-07-31 | 2022-10-03 | アクラリス セラピューティクス，インコーポレイテッド | 重水素化ｍｋ２経路阻害剤およびその使用方法 |
| US20230087078A1 (en) | 2020-03-02 | 2023-03-23 | Washington University | Compositions and methods for the treatment of pancreatic cancer |
| KR20220161396A (ko) | 2020-03-27 | 2022-12-06 | 어클라리스 쎄라퓨틱스, 인코포레이티드 | 치환된 피리디논-피리디닐 화합물의 제조, 조성물, 및 결정형 |
-
2021
- 2021-03-26 KR KR1020227037292A patent/KR20220161396A/ko not_active Withdrawn
- 2021-03-26 JP JP2022558423A patent/JP2023519890A/ja active Pending
- 2021-03-26 CN CN202411432060.0A patent/CN119235863A/zh active Pending
- 2021-03-26 IL IL296054A patent/IL296054A/en unknown
- 2021-03-26 PH PH1/2022/552321A patent/PH12022552321A1/en unknown
- 2021-03-26 PH PH1/2022/552263A patent/PH12022552263A1/en unknown
- 2021-03-26 JP JP2022558424A patent/JP2023519891A/ja active Pending
- 2021-03-26 BR BR112022019349A patent/BR112022019349A2/pt not_active Application Discontinuation
- 2021-03-26 AU AU2021244255A patent/AU2021244255A1/en not_active Abandoned
- 2021-03-26 CN CN202411390540.5A patent/CN119454711A/zh active Pending
- 2021-03-26 WO PCT/US2021/024376 patent/WO2021195507A1/en not_active Ceased
- 2021-03-26 US US17/907,516 patent/US20230149400A1/en active Pending
- 2021-03-26 CA CA3172088A patent/CA3172088A1/en active Pending
- 2021-03-26 EP EP21776610.4A patent/EP4132524A4/en not_active Withdrawn
- 2021-03-26 CA CA3172203A patent/CA3172203A1/en active Pending
- 2021-03-26 KR KR1020227037183A patent/KR20220161390A/ko not_active Withdrawn
- 2021-03-26 MX MX2022011748A patent/MX2022011748A/es unknown
- 2021-03-26 MX MX2022011755A patent/MX2022011755A/es unknown
- 2021-03-26 CN CN202180037711.4A patent/CN115666566A/zh active Pending
- 2021-03-26 WO PCT/US2021/024316 patent/WO2021195475A1/en not_active Ceased
- 2021-03-26 US US17/214,532 patent/US11844801B2/en active Active
- 2021-03-26 WO PCT/US2021/024482 patent/WO2021195562A1/en not_active Ceased
- 2021-03-26 EP EP21775856.4A patent/EP4125891A4/en not_active Withdrawn
- 2021-03-26 CN CN202180032410.2A patent/CN115484952B/zh not_active Expired - Fee Related
- 2021-03-26 AU AU2021244609A patent/AU2021244609A1/en not_active Abandoned
-
2023
- 2023-11-08 US US18/504,778 patent/US12370195B2/en active Active
-
2025
- 2025-06-25 US US19/249,611 patent/US20250387393A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021195475A1 (en) | 2021-09-30 |
| US20210338669A1 (en) | 2021-11-04 |
| EP4125891A4 (en) | 2024-08-21 |
| EP4132524A4 (en) | 2025-06-04 |
| CN119454711A (zh) | 2025-02-18 |
| IL296054A (en) | 2022-10-01 |
| CA3172088A1 (en) | 2021-09-30 |
| AU2021244609A1 (en) | 2022-09-15 |
| JP2023519891A (ja) | 2023-05-15 |
| US12370195B2 (en) | 2025-07-29 |
| US11844801B2 (en) | 2023-12-19 |
| AU2021244255A1 (en) | 2022-09-29 |
| EP4125891A1 (en) | 2023-02-08 |
| KR20220161396A (ko) | 2022-12-06 |
| CN115666566A (zh) | 2023-01-31 |
| CN115484952B (zh) | 2024-10-18 |
| CA3172203A1 (en) | 2021-09-30 |
| BR112022019349A2 (pt) | 2022-11-16 |
| KR20220161390A (ko) | 2022-12-06 |
| CN115484952A (zh) | 2022-12-16 |
| JP2023519890A (ja) | 2023-05-15 |
| WO2021195507A1 (en) | 2021-09-30 |
| WO2021195562A1 (en) | 2021-09-30 |
| US20250387393A1 (en) | 2025-12-25 |
| CN119235863A (zh) | 2025-01-03 |
| MX2022011755A (es) | 2022-11-16 |
| US20230149400A1 (en) | 2023-05-18 |
| US20230242505A1 (en) | 2023-08-03 |
| PH12022552263A1 (en) | 2023-11-13 |
| PH12022552321A1 (en) | 2023-12-04 |
| US20240197732A1 (en) | 2024-06-20 |
| EP4132524A1 (en) | 2023-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022011748A (es) | Composiciones orales de inhibidor de ruta de mk2 para el tratamiento de condiciones inmunitarias. | |
| GEAP202416515A (en) | Quinoline compounds as inhibitors of kras | |
| CY1115289T1 (el) | Μεθοδοι αγωγης εναντι ασθενειας που σχετιζεται με φλεγμονη | |
| EA202090676A1 (ru) | Способы введения некоторых vmat2-ингибиторов | |
| AR060089A1 (es) | Tratamiento del dolor | |
| SV2002000036A (es) | Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11111/rm/ma | |
| WO2021168483A3 (en) | Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors | |
| DOP2022000076A (es) | Inhibidores del factor d del complemento para administración oral | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| AR128257A1 (es) | Compuestos y composiciones para tratar afecciones relacionadas con la actividad de sting | |
| AR110800A1 (es) | MÉTODOS PARA AUMENTAR EN PLASMA SANGUÍNEO LA 2-DESOXIURIDINA (dUrd) Y LA INHIBICIÓN DE LA TIMIDILATO SINTASA | |
| DOP2022000074A (es) | Inhibidores del factor d del complemento para administración oral | |
| SA523440403B1 (ar) | Magl مثبط | |
| PH12019500242A1 (en) | 9-aminomethyl minocycline compounds and uses thereof | |
| MX2022006052A (es) | Inhibidores de la caspasa 6 y usos de los mismos. | |
| JOP20250122A1 (ar) | تركيبة صيدلانية للوقاية من قرحة المعدة المرتبطة بالعقاقير أو علاجها، مكونة من زاستابرازان أو ملح مقبول صيدلانيًا منه | |
| CL2021003303A1 (es) | Tratamiento para sinucleinopatías. | |
| CY1105787T1 (el) | Θepαπευτικη αντιμετωπιση η προληψη της ατροφιας του ουροποιογεννητικου συστηματος και τα συμπτωματα της σε γυναικες | |
| MX2023009620A (es) | Metodos terapeuticos. | |
| AR128051A1 (es) | Inhibidores de parp1 | |
| UY39466A (es) | Compuestos y composiciones para el tratamiento de la criptosporidiosis | |
| PH12022552715A1 (en) | Pharmaceutical composition comprising benzimidazole derivative compound | |
| CY1113544T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει ενα συνδυασμο που σχηματιζεται απο τον αντιμικροβιακο παραγοντα σιπροφλοξασινη και τον αντιοξειδωτικο παραγοντα ασκορβικο οξυ για τη θεραπεια λοιμωξεων του ουροποιητικου συστηματος | |
| EA202090416A1 (ru) | Способы лечения симптомов гастропареза с использованием велусетрага | |
| PE20260134A1 (es) | Composiciones y metodos para el tratamiento de la hiperplasia suprarrenal congenita |